JP Morgan Chase’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
Other funds holding BIO
VCM
VPM
AI
JP Morgan Chase's BIO Position: Q1 2026 in Review
JP Morgan Chase increased its Bio-Rad Laboratories Class A (BIO) stake by 84% in Q1 2026, buying an estimated $13M and bringing the position to 99,391 shares worth $26.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1839.
JP Morgan Chase first reported a position in BIO in Q2 2013 and has held it in 52 quarters since. The position peaked at $33.2M in Q2 2021. 393 funds tracked by Wall St. Rank hold BIO as of Q1 2026.
- JP Morgan Chase held 99,391 shares of Bio-Rad Laboratories Class A worth $26.9M as of Q1 2026.
- JP Morgan Chase bought 45,272 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $13M.
- Bio-Rad Laboratories Class A made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1839 holding.
- JP Morgan Chase first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 52 quarters since.
- JP Morgan Chase's Bio-Rad Laboratories Class A position peaked at $33.2M in Q2 2021.
- 393 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.